P. McLaughlin, L. Odom, P. Arnett, G. Thomas, Shannon Orehek, I. Zagon
{"title":"Length of Disease More than Therapy Impacts Anxiety and Depression in Multiple Sclerosis","authors":"P. McLaughlin, L. Odom, P. Arnett, G. Thomas, Shannon Orehek, I. Zagon","doi":"10.33425/2692-7918.1043","DOIUrl":null,"url":null,"abstract":"Persons with multiple sclerosis (PwMS) often report a reduced quality of life related to their anxiety and depression associated with the biological unknowns of MS. The COVID-19 pandemic increased the risk of anxiety due to the uncertainties related to vaccine efficacy and immune-suppressing disease-modifying therapies. PwMS were recruited from the Neurology Clinic of the Penn State Hershey Medical Center and asked to complete a demographic questionnaire and surveys on depression (MS-Beck Depression Inventory, MS-BDI) and the Hospital Anxiety and Depression Scale (HADS). The rationale for the study is to determine whether treatment modalities, age, and length of disease impacted anxiety and/or depression in PwMS. Data from 150 participants were included in the analyses. The overall mean age was 54.6 years with a 3.7:1 female:male ratio and mean length of disease of approximately 17 years. Mean scores of the HADS-D, and high scores (> 8) were 4.68 ± 0.3 and 10.0 ± 0.32, respectively, with no differences between males and females. The mean HADS-A score was 6.15 ± 0.36 with significant differences recorded between male and females. The mean high HADS-A score was 10.77 ± 0.40, with no differences between sexes. The mean MS-BDI score was 4.15 ± 0.7 with no differences between males and females. Analyses of anxiety scores in relationship to length of disease revealed no differences between males and females. Anxiety scores did not differ for PwMS on different disease-modifying therapies. In conclusion, the number of years that PwMS had the disease impacted anxiety levels more than the age or treatment regimen..","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.33425/2692-7918.1043","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Persons with multiple sclerosis (PwMS) often report a reduced quality of life related to their anxiety and depression associated with the biological unknowns of MS. The COVID-19 pandemic increased the risk of anxiety due to the uncertainties related to vaccine efficacy and immune-suppressing disease-modifying therapies. PwMS were recruited from the Neurology Clinic of the Penn State Hershey Medical Center and asked to complete a demographic questionnaire and surveys on depression (MS-Beck Depression Inventory, MS-BDI) and the Hospital Anxiety and Depression Scale (HADS). The rationale for the study is to determine whether treatment modalities, age, and length of disease impacted anxiety and/or depression in PwMS. Data from 150 participants were included in the analyses. The overall mean age was 54.6 years with a 3.7:1 female:male ratio and mean length of disease of approximately 17 years. Mean scores of the HADS-D, and high scores (> 8) were 4.68 ± 0.3 and 10.0 ± 0.32, respectively, with no differences between males and females. The mean HADS-A score was 6.15 ± 0.36 with significant differences recorded between male and females. The mean high HADS-A score was 10.77 ± 0.40, with no differences between sexes. The mean MS-BDI score was 4.15 ± 0.7 with no differences between males and females. Analyses of anxiety scores in relationship to length of disease revealed no differences between males and females. Anxiety scores did not differ for PwMS on different disease-modifying therapies. In conclusion, the number of years that PwMS had the disease impacted anxiety levels more than the age or treatment regimen..
期刊介绍:
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.